SEC Filing Summary: Cara Therapeutics, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Cara Therapeutics, Inc. on January 10, 2022. The report discloses the company's financial position as of December 31, 2021, and the release of an updated corporate presentation for the 40th Annual J.P. Morgan Healthcare Conference.
Key Financial Metrics
- Cash Position: $237 million as of December 31, 2021.
- Debt: No debt outstanding.
- Shares Outstanding: 53 million shares of common stock.
- Revenue, Profit, and Margins: The filing text does not provide specific values for revenue, net income, operating margins, or cash flow for the period.
Material Changes and Outlook
The filing does not explicitly detail material changes compared to prior periods or provide specific forward-looking guidance on revenue or earnings. The primary disclosure is the update to the company's liquidity position and the release of strategic information via a corporate presentation.
Important Facts for Investor Verification
- Verify the $237 million cash balance as of December 31, 2021, against the company's most recent audited financial statements.
- Confirm the 53 million shares of common stock outstanding figure.
- Review the attached Corporate Presentation (Exhibit 99.1) for detailed strategic updates and clinical pipeline status not included in this summary.
- Note that the information provided in this 8-K is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other SEC filings.